Filing Flows › RenovoRx (RNXT) › Q1 2026
RenovoRx (RNXT) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
RenovoRx (RNXT) reported revenue of $563K for the first quarter 2026 (Q1 2026), +186% from a year earlier and +137% from the quarter before. Operating margin was -616.2%, net loss $3.5M (625.4% of revenue).
RenovoRx, Q1 2026: revenue $563K (+186% year over year), operating margin -616.2%, net loss $3.5M, operating cash flow −$3.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $563K | +137% | +186% |
| Operating profit | −$3.5M | — | — |
| Net earnings | −$3.5M | — | — |
| Operating cash flow | −$3.7M | — | — |
What changed
Revenue was $563K in Q1 2026, up 186% year over year and up 137% from the previous quarter.
Gross margin was 85.1%, up 32.8 points from Q1 2025. Operating costs exceeded revenue by $3.5M, an operating margin of -616.2%. Operating expenses grew 23% against revenue growth of 186%. The fastest-growing cost line was SG&A (+73%). The quarter ended with a net loss of $3.5M, wider than the previous quarter's $2.9M loss.
Operating cash flow was −$3.7M. Non-cash charges added back $1K of depreciation and $317K of share-based compensation. Working capital and other items used $506K.
Questions
What was RenovoRx's revenue in the first quarter 2026?
RenovoRx (RNXT) reported revenue of $563K for the first quarter 2026 (Q1 2026), +186% from a year earlier and +137% from the quarter before.
Was RenovoRx profitable in the first quarter 2026?
Operating loss was $3.5M (-616.2% of revenue) and net loss $3.5M.
Source: RenovoRx 10-Q on SEC EDGAR.